Last updated: March 2026
Everything you need to know about sourcing retatrutide (LY3437943) — the triple-agonist peptide that produced up to 24.2% weight loss in Phase 2 trials. Current availability, pricing, and what to watch for.
Retatrutide (LY3437943) is the first triple hormone receptor agonist — targeting GIP, GLP-1, and glucagon receptors simultaneously. Developed by Eli Lilly, it represents the next generation of weight loss peptides beyond dual agonists like tirzepatide.
Activates GIP, GLP-1, and glucagon receptors — the first drug to target all three simultaneously for weight management.
Developed by Eli Lilly and Company. Currently in Phase 3 clinical trials under the TRIUMPH program.
The 12mg dose group achieved 24.2% mean body weight loss at 48 weeks in the Phase 2 trial (Jastreboff et al., NEJM 2023).
Why the excitement? Retatrutide's triple mechanism adds glucagon receptor activation to the GIP/GLP-1 agonism seen in tirzepatide. The glucagon component may increase energy expenditure and promote fat oxidation, potentially explaining the superior weight loss results.
Retatrutide is not FDA approved. It remains an investigational drug. Here's the development timeline.
Jastreboff et al. published Phase 2 data in the New England Journal of Medicine showing up to 24.2% weight loss at 48 weeks with the 12mg dose.
Eli Lilly launched multiple Phase 3 trials (TRIUMPH-1 through TRIUMPH-4) evaluating retatrutide for obesity and type 2 diabetes.
Large-scale trials enrolling thousands of participants are currently underway. Results expected to read out in 2026.
If Phase 3 results are positive, Eli Lilly could submit a New Drug Application (NDA) to the FDA. Approval, if granted, would come 10–12 months after submission.
Earliest potential availability as a prescription medication. Supply constraints are likely initially, similar to the tirzepatide (Mounjaro/Zepbound) launch.
Important: These timelines are estimates based on typical regulatory processes. Delays are common in drug development. There is no guarantee retatrutide will receive FDA approval.
Since retatrutide is not available by prescription, people who use it currently obtain it through one of two channels:
Online peptide vendors sell synthetic retatrutide labeled "for research purposes only" or "not for human consumption." This is the gray market — a legal gray area where compounds are sold for in-vitro research. Buyers assume all risk.
Enrollment in Eli Lilly's TRIUMPH Phase 3 program. Participants receive retatrutide (or placebo) under medical supervision at no cost. Check ClinicalTrials.gov for open enrollment sites.
Gray market reality: Research peptide vendors operate in a legal gray area. Products are not FDA-regulated, may vary in purity, and are sold without medical oversight. There are real risks: contamination, incorrect dosing, and no recourse if something goes wrong. This is not the same as getting a prescription from your doctor.
Certificates of Analysis from independent labs. Look for HPLC purity testing (≥98%) and mass spectrometry confirmation. COAs should be batch-specific, not generic.
Community forums and subreddits where users share testing results and experiences. Established vendors with multi-year track records carry lower risk than new sellers.
Credit card processing is common among established vendors. Crypto-only vendors aren't necessarily bad, but credit cards offer chargeback protection. Watch for vendors that only accept wire transfers.
Peptides are fragile. Reputable vendors ship lyophilized (freeze-dried) powder in sealed vials with cold packs. Domestic shipping reduces transit time and customs risk.
Research-grade retatrutide pricing varies by vendor, quantity, and purity. Here's what to expect in 2026.
| Vial Size | Typical Price Range | Notes |
|---|---|---|
| 5mg vial | $40 – $80 | Most common size. Enough for several weeks at lower doses. |
| 10mg vial | $70 – $140 | Better per-mg value. Preferred by those using higher doses. |
| 15mg+ vials | $100 – $200 | Less commonly available. Bulk pricing varies significantly. |
Cost context: These are research chemical prices. If/when retatrutide receives FDA approval, the branded prescription price will likely be significantly higher — potentially $500–$1,000+/month based on comparable GLP-1 drug pricing (e.g., Zepbound list price ~$1,059/month). Check our price comparison tool for current vendor pricing.
Beyond the peptide itself, reconstitution and administration require bacteriostatic water, insulin syringes, alcohol swabs, and proper storage. Budget an additional $20–$40 for supplies.
Use our reconstitution calculator to determine the correct water volume and dosing concentration for your vial size.
Retatrutide comes as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use.
Slowly inject bacteriostatic water along the vial wall. Do not spray directly onto the powder. Common: 1–2 mL per 5mg vial.
Let the water dissolve the peptide. Gentle swirling is fine — never shake vigorously. Allow a few minutes for full dissolution.
Store reconstituted peptide at 2–8°C (standard refrigerator). Use within 4–6 weeks. Calculate your dose volume with our tool.
The Phase 2 trial (Jastreboff et al., NEJM 2023) used a dose-escalation protocol with weekly subcutaneous injections. The 12mg group achieved the highest weight loss.
Source: Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity." N Engl J Med. 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972
Dose escalation matters. The gradual ramp-up is critical for tolerability. Jumping straight to high doses significantly increases GI side effects. The trial protocol was designed to minimize nausea and other adverse events during escalation.
For help calculating injection volumes based on your reconstitution, visit our retatrutide dosing calculator or see the full clinical trial data breakdown.
Retatrutide is an investigational drug with limited safety data. The Phase 2 trial identified common side effects, but long-term safety is unknown.
Approximate rates from the 12mg dose group. GI side effects were generally mild-to-moderate and decreased after dose escalation. Source: Jastreboff et al., NEJM 2023.
Research peptide risks: Research-grade peptides are not manufactured under pharmaceutical-grade GMP conditions. Risks include contamination, incorrect peptide identity, sub-potent or super-potent products, and sterility issues. There is no regulatory oversight of these products. Always consult a qualified healthcare provider before using any investigational compound.
Swiss Chems carries retatrutide for research purposes. One of the most trusted peptide suppliers with third-party COA testing.
Affiliate link helps support MeetPeptide at no extra cost to you.
If you're researching peptide reconstitution, these are the supplies commonly used. Affiliate links help support MeetPeptide at no extra cost to you.
Affiliate links help support MeetPeptide at no extra cost to you.
Explore more retatrutide information and peptide tools on MeetPeptide.
⚕️ This page is for educational and informational purposes only. It is not medical advice. Retatrutide (LY3437943) is an investigational drug not approved by the FDA. Always consult with a qualified healthcare provider. Data sourced from published peer-reviewed research.